These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 32020379)
1. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Sonoda Y Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379 [TBL] [Abstract][Full Text] [Related]
2. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105 [TBL] [Abstract][Full Text] [Related]
4. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
5. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642 [TBL] [Abstract][Full Text] [Related]
6. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
7. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
9. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases. Lee B; Hwang S; Bae H; Choi KH; Suh YL Brain Pathol; 2024 Sep; 34(5):e13234. PubMed ID: 38217295 [TBL] [Abstract][Full Text] [Related]
11. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
13. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Komori T Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304 [TBL] [Abstract][Full Text] [Related]
14. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
15. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
16. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification. Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630 [TBL] [Abstract][Full Text] [Related]
17. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
18. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545 [TBL] [Abstract][Full Text] [Related]
19. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]